Comparative Effectiveness Study Examines Addition to Standard of Care for Ovarian Cancer
A recent study compared the effects of the standard of care alone versus combining the standard treatment with a tyrosine kinase inhibitor (TKI) for patients with recurrent epithelial ovarian cancer, published in JAMA Oncology (online December 14, 2017; doi:10.1001/jamaoncol.2017.2418).
Adding pazopanib to weekly paclitaxel did not significantly improve progression-free survival in women with recurrent ovarian cancer, the study found.
The finding stems from a double-blind phase 2 trail that randomized 106 women with recurrent ovarian cancer to either weekly intravenous paclitaxel plus daily oral pazopanib or weekly intravenous paclitaxel plus daily oral placebo.
The median progression-free survival for women who received pazopanib added to paclitaxel was 7.5 months, researchers reported, compared with 6.2 months for women who received paclitaxel alone. Median overall survival for women who received added pazopanib was 20.7 months compared with 23.3 months for those who received only paclitaxel.
Meanwhile, severe hypertension was more common among women who received added pazopanib, and more women in the added-pazopanib group (37%) discontinued treatment because of adverse events than in the paclitaxel-alone group (9.6%). However, more women receiving paclitaxel alone discontinued treatment for disease progression (65.4% versus 31.5% with added pazopanib).
Combining pazopanib with paclitaxel in the treatment of women with recurrent ovarian cancer, researchers concluded, is not superior to paclitaxel alone.—Jolynn Tumolo